The partnership with OpenAI is seen as a significant positive development for Moderna, likely to enhance its research capabilities and potentially lead to groundbreaking advancements in mRNA medicine. This has been positively received by the market, as reflected in the increase in Moderna's stock price. The collaboration is expected to leverage OpenAI's advanced AI technologies to accelerate Moderna's drug discovery and development processes, which could result in more efficient and effective treatments being brought to market faster.